Peptide profiles and research guides for GLP-1 agonists, weight management, and metabolic health.
NNMT Inhibitor
A small molecule NNMT inhibitor that promotes fat loss and metabolic health by raising cellular NAD+ levels.
HGH Fragment
A fragment of human growth hormone that targets fat metabolism without the growth-promoting effects of full HGH.
Metabolic Optimization Complex
A triple metabolic complex targeting mitochondrial uncoupling, ERR agonism, and cellular aging for comprehensive metabolic optimization.
Amylin Receptor Agonist
A long-acting amylin analog that complements GLP-1 therapy for superior weight loss and metabolic control.
Oral GLP-1 + ERR Agonist Blend
An oral GLP-1 receptor agonist combined with an ERRα/γ agonist for comprehensive metabolic optimization.
Triple GIP/GLP-1/Glucagon Receptor Agonist
A triple agonist targeting GIP, GLP-1, and glucagon receptors — showing up to 24.2% weight loss in Phase II trials.
GLP-1 Receptor Agonist
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management with robust cardiovascular benefits.
Metabolic Optimization Blend
A synergistic metabolic blend combining ERR agonism and NNMT inhibition for comprehensive fat loss and metabolic health.
Exercise Mimetic / ERR Agonist
An ERRα/γ agonist that mimics the metabolic effects of endurance exercise at the molecular level.
Triple Monoamine Reuptake Inhibitor
A triple monoamine reuptake inhibitor with potent appetite suppression and weight loss effects.
GIP/GLP-1 Dual Receptor Agonist
The first dual GIP/GLP-1 receptor agonist, demonstrating superior weight loss outcomes compared to GLP-1 monotherapy.